Stakeholders must alter their mindsets when it comes to early-phase design and interpreting regulatory guidance for CGT trials.
Amy Raymond, PhD, PMP
Advertisement
Senior Director, Therapeutic Strategy Lead, Rare Disease, Worldwide Clinical Trials
Articles by Amy Raymond, PhD, PMP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years
3
Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention
4
A Shot in the Arm to Traditional Vaccine Trial Strategy
5